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Abstract:
Afobazole is an anxiolytic medication that has been previously shown to be neuroprotective both in vitro and in vivo. However, the mechanism(s) by which afobazole can enhance neuronal survival remain poorly understood. Experiments were carried out to determine if afobazole can decrease intracellular calcium overload associated with ischemia and acidosis, and if the effects of afobazole are mediated via interaction of the compound with σ receptors. Fluorometric Ca 2+ imaging was used to resolve how application of afobazole affects intracellular Ca 2+ handling in cortical neurons. Application of afobazole significantly depressed, in a concentration-dependent and reversible manner, the intracellular Ca 2+ overload resulting from in vitro ischemia and acidosis. The IC 50 for afobazole inhibition of ischemia-evoked intracellular Ca 2+ overload was considerably less than for inhibition of [Ca 2+ ] i increases induced by acidosis. However, afobazole maximally inhibited only 70% of the ischemia-evoked intracellular Ca 2+ overload but effectively abolished intracellular Ca 2+ increases produced by acidosis. The effects of afobazole on ischemia-and acidosis-induced intracellular Ca 2+ dysregulation were inhibited by preincubating the neurons in the irreversible, pan-selective σ receptor antagonist, metaphit.
Moreover, the effects of afobazole on intracellular Ca 2+ increases triggered by acidosis and ischemia were blocked by the selective σ-1 receptor antagonists, BD 1063 and BD 1047, respectively. Experiments examining the effects of afobazole on neuronal survival in response to ischemia showed that afobazole was neuroprotective. Taken together, these data suggest that afobazole regulates intracellular Ca 2+ overload during ischemia and acidosis via activation of σ-1 receptors. This mechanism is likely responsible for afobazole-mediated neuroprotection.
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Introduction:
Afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole) is an anxiolytic that was approved for clinical use in Russia in 2005. In addition to the anxiolytic properties, afobazole has been shown to decrease neuronal death in vitro in response to oxidative stress and glutamate excitotoxicity (Zenina et al., 2005) . In vivo, afobazole has been shown to be neuroprotective in a rat cerebral hemorrhage model and a rat prefrontal cortex photothrombosis model (Galaeva et al., 2005; Seredenin et al., 2008) . Several mechanisms have been proposed to mediate these neuroprotective effects of afobazole, including inhibition of nitric oxide synthase and increased superoxide dismutase activity (Seredenin et al., 2008) . In addition, it has also been suggested that modulation of GABAergic transmission and regulation of brainderived neurotrophic factor may contribute to the beneficial effects of afobazole in various pathophysiological models (Zenina et al., 2005; Szanyi et al., 2007; Seredenin et al., 2008) .
However, the molecular mechanisms underlying afobazole-mediated neuroprotection remain poorly understood.
The chemical structure of afobazole shares pharmacophore structure with the σ-1 receptor ligand, (+)-pentazocine (Walker et al., 1990) , which motivated a recent study on the interaction of afobazole with these receptors (Seredenin et al., 2009 (Seredenin et al., 2009 ). Moreover, afobazole was found to promote mobilization of σ-1 receptors to the plasma membrane in HT-22 cells, also suggesting an afobazole-σ-1 receptor interaction (Seredenin et al., 2009 ). However, it has not been established if afobazole functions as an agonist or an antagonist at σ-1 receptors. Furthermore, the role of σ-1 receptors in afobazole-mediated neuroprotection remains unknown.
This article has not been copyedited and formatted. The final version may differ from this version. produced by both in vitro ischemia and acidosis (Katnik et al., 2006; Herrera et al., 2008) . This inhibition of intracellular Ca 2+ dysregulation is mediated via the inhibition of multiple ion channel types, including the acid-sensing ion channel 1a, ASIC1a (Katnik et al., 2006; Herrera et al., 2008) . The inhibition of these multiple pathways likely accounts for the fact that stimulation of σ receptors in vivo decreases neuronal injury in a rat model of ischemic stroke even when these receptors are activated 24 hours after onset of ischemia (Ajmo et al., 2006) . Given the fact that afobazole shares pharmacophore structure with the σ-1 agonist, (+)-pentazocine, these receptors represent a putative target for afobazole-mediated neuroprotection.
Experiments were carried out to determine the effects of afobazole on intracellular Ca 2+ overload produced by ischemia and acidosis in cortical neurons. Furthermore, the role of σ receptors on afobazole regulation of neuronal responses to these pathophysiological states was examined. Afobazole was found to significantly depress the intracellular Ca 2+ dysregulation triggered by ischemia and acidosis. Moreover, afobazole was found to enhance neuronal survival during in vitro ischemia. Inhibition of σ receptors via the pan-selective antagonist, metaphit, decreased the effectiveness of afobazole in both the ischemia and acidosis assays.
Experiments using the σ-1 selective antagonists, BD 1047 and BD 1063, showed that this receptor is specifically involved in the effects of afobazole in neurons.
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Primary Rat Cortical Neuron Preparation
Primary cortical neurons were isolated from embryonic (E18) rats and cultured as previously described by our laboratory (Katnik et al., 2006) . All procedures were done in accordance with the regulations of the University of South Florida Institutional Animal Care and Use Committee. Neurons grown in culture for 10-21 days were used for this study.
Calcium imaging measurements
The effects of afobazole on ischemia-and acidosis-evoked changes in intracellular Ca 2+ concentrations in neurons were examined using fluorescent imaging techniques with fura-2 as the indicator (Katnik et al., 2006) . Cells plated on coverslips were incubated for 1 hour at room temperature in Neurobasal (Invitrogen) medium supplemented with B27 (Invitrogen) and 0.5 mM l-glutamine, or in physiological saline solution (PSS) consisting of (in mM): 140 NaCl, 5.4
KCl, 1.3 CaCl 2 , 1.0 MgCl 2 , 20 glucose, and 25 HEPES (pH to 7.4 with NaOH). Both solutions contained 3 μM acetoxymethyl ester fura-2 and 0.3 % dimethyl sulfoxide. The coverslips were washed in fura-2-free PSS prior to the experiments.
Electrophysiology recordings
Acidosis-evoked membrane currents were recorded from neurons as described previously (Herrera et al., 2008) . Briefly, cortical neurons were plated on glass coverslips (as described above) and cultured for 10-14 days. Electrical access was achieved using the perforated-patch method with amphotericin B to preserve intracellular integrity of neurons (Rae et al., 1991 
Solutions and reagents
The control bath solution for all experiments was PSS. All drugs were applied in this solution using a rapid application system identical to that previously described (Cuevas and Berg, 1998) . Afobazole, DTG, and the reversible sigma-1 receptor antagonists, BD 1063 and BD 1047, were applied for 5 min before cells were exposed to either ischemia or acidosis. In experiments in which BD1063 and BD 1047 were used to inhibit the effects of afobazole, these drugs were applied for 5 min prior to, and then during the course of, afobazole treatment.
Changes in [Ca
2+
] i were elicited by either applying PSS with a pH of 6.0 or via induction of chemical ischemia (glucose-free PSS containing 4 mM azide) as previously described (Mari et al., 2010) . Individual cells were exposed to no more than four challenges with either low pH or ischemia to prevent rundown of the responses. All chemicals used in this investigation were of 
Data analysis
Analyses of measured intracellular Ca 2+ and membrane current responses were conducted using Clampfit 9 (Axon instruments). Imaging data files collected with SlideBook 4.02 (Intelligent ] i in the neurons ( Figure 1A ), consistent with previous reports (Herrera et al., 2008) . In the presence of afobazole, the increase in [Ca 2+ ] i was reduced ( Figure 1A ) and this inhibition was reversible (data not shown observed during acidosis (Herrera et al., 2008) . Much of the proton-evoked increases in [Ca 2+ ] i are due to the opening of channels downstream of ASIC (Herrera et al., 2008) . To determine if afobazole is blocking ASIC or only downstream effector targets of these channels, patch-clamp electrophysiological recordings were carried out. Figure 2A shows proton-evoked membrane currents recorded in the absence and presence of 300 μM afobazole from a neuron held at a membrane potential of -70 mV. Application of protons evoked a rapid inward current, which was reduced by afobazole. In a second neuron, application of psalmotoxin 1 (PcTx), and inhibitor of homomeric ASIC1a channels (Chen et al., 2005) , decreased proton-evoked current amplitude, and co-application of afobazole (300 μM) with PcTx resulted in further reduction in current amplitude ( Figure 2B ). In identical experiments, afobazole inhibited proton-evoked current by 18 ± 2% and 50 ± 11% in the absence and presence of PcTx, respectively. Thus, afobazole has greater effects on the PcTx-insensitive component of the proton-evoked current, which is likely mediated by ASIC1a/ASIC2a heteromeric channels (Escoubas et al., 2000; Askwith et al., 2004) .
Given that afobazole shares pharmacophore structure with the σ-1 agonist, pentazocine, experiments were conducted to determine if σ receptors are involved in the inhibition of acidosis-evoked increases in [Ca 2+ ] i by afobazole. For these experiments we used the irreversible σ receptor antagonist, metaphit, which blocks both σ-1 and σ-2 receptors. Similarly, the inhibition of net increase in [Ca 2+ ] i by afobazole was reduced from 41 ± 2% in control cells to 27 ± 1% when cells were preincubated in metaphit ( Figure 3C ). These decreases were statistically significant (p < 0.001).
To determine if σ-1 receptors were specifically involved in afobazole regulation of acidevoked increases in [Ca 2+ ] i , the σ-1-selective antagonist, BD 1063, was used to disrupt afobazole signaling. Figure 4A shows decreased from 55 ± 3% to 24 ± 6% in the presence of the σ-1 antagonist.
The ion channels which stimulate acidosis-evoked increases in [Ca 2+ ] i in cortical neurons, acid-sensing ion channel 1a (ASIC1a), also contribute to the elevations in [Ca 2+ ] i in these neurons during ischemia (Mari et al., 2010 Figure 5A , lower traces).
However, higher concentrations of DTG were required to produce inhibitions equal to those by afobazole. Figure 5B shows concentration response relationships for afobazole and DTG μM, afobazole produced a statistically greater block than DTG. However, DTG exhibited greater efficacy than afobazole by blocking over 70% of the response at the highest concentrations tested ( Figure 5B ). To determine the specific σ receptor subtype involved in the modulation of ischemiainduced [Ca 2+ ] i overload experiments were carried out using the σ-1 receptor-selective antagonist, BD 1047. A representative experiment on an isolated cortical neuron using this drug is shown in Figure 7A . Application of 300 μM afobazole depressed the [Ca 2+ ] i overload elicited by in vitro ischemia in the neuron. However, when afobazole was co-applied with 10 μM BD 1047, the effects of afobazole were reduced ( Figure 7A ). Using this same protocol, it was determined that application of BD 1047 (10 μM) reduced the effects of afobazole on both peak and net elevations in [Ca 2+ ] i in neurons ( Figure 7B ). In the presence of BD 1047 the percent inhibition of peak and net [Ca 2+ ] i overload produced by 300 μM afobazole were reduced by 29 ± 4% and 34 ± 5%, respectively ( Figure 7C ). neuronal death in response to in vitro ischemia. Cultured neurons were exposed to a combination of oxygen-glucose deprivation and 4 mM azide for 2 hours in order to stimulate ischemia-induced cell death. Neuronal death was quantified using an LDH cytotoxicity assay. Figure 9A shows the relative degree of cell death observed with or without ischemia under control conditions (no drug) and when DTG and afobazole were applied at the indicated concentrations (in μM). Both afobazole and DTG significantly decreased neuronal death following ischemia in a concentration-dependent manner. Consistent with data shown in Figure   5 , afobazole was more potent than DTG, whereby identical concentrations of afobazole decreased cell death to a greater extent than DTG. Further analysis of the data from Figure 9A indicates that afobazole reduced neuronal death by 17%-20% more than DTG at identical concentrations, with 100 μM afobazole decreasing neuronal death by 39 ± 1% ( Figure 9B ). (Zenina et al., 2005) . The molecular mechanism(s) accounting for afobazole-mediated neuroprotection remained unknown. A recent study showed that afobazole decreased caspase-3 activity in response to glutamate excitotoxicity in the immortalized neuronal cell line, HT-22 (Antipova et al., 2010) .
However, it is unclear if afobazole is acting directly on caspase-3 or through some upstream signaling molecule. Another putative afobazole target for neuroprotection is σ receptors, which have been postulated as an effector for this drug (Seredenin et al., 2009) ] i overload. The concentration of metaphit and the percent inhibition of the afobazole effects it produced are consistent with these effects being mediated by σ receptors (Katnik et al., 2006; Herrera et al., 2008) . Furthermore, it was found that the σ-1 receptor-selective antagonist, BD 1063, inhibits the effects of afobazole on acidosis-evoked [Ca 2+ ] i overload at a concentration indicative of a σ-1 receptor mediated effect (Matsumoto et al., 1995; Herrera et al., 2008) . Similarly, BD 1047, which is also selective for σ-1 (Matsumoto et al., 1995) and has been shown to disrupt σ-1 receptor-mediated inhibition of ischemia-induced [Ca 2+ ] i overload (Katnik et al., 2006) blocked the effects of afobazole in our in vitro ischemia model. Taken together, our data suggest that afobazole acts as a σ receptor agonist and that it specifically activates σ-1 receptors.
Additional data collected in our laboratory suggests that afobazole may also act as a σ-2 receptor agonist (Cuevas et al., in preparation) . Given that neither metaphit nor the σ-1receptor-selective antagonists completely eliminated the effects of afobazole, the possibility exists that this drug is ] i overload occurring under these conditions is due to the activation of multiple plasma membrane ion channels, including acid-sensing ion channels, voltage-gated Ca 2+ channels and ionotropic glutamatergic receptors (Katnik et al., 2006; Herrera et al., 2008) . Neuronal injury has been directly linked to some of these channels, such as the acidsensing ion channel 1a (Xiong et al., 2004) . Sigma receptors couple to these various channel types and suppress their activity (Zhang and Cuevas, 2002; Zhang and Cuevas, 2005; Katnik et al., 2006; Herrera et al., 2008; Zhang et al., 2009 ). Thus, the effects of afobazole are likely due to a broad-spectrum inhibition of plasma membrane ion channels downstream of σ receptors.
Interestingly, our data indicate that ASICs expressed in cortical neurons are inhibited by afobazole application. Both proton-evoked membrane currents and increases in [Ca 2+ ] i were reduced by afobazole. These neurons functionally express homomeric ASIC1a and ASIC2a channels, as well as heteromeric express ASIC1a/ASIC2a channels . The pH-and PcTx1-sensitivity of the channels affected by afobazole suggests that the drug is likely acting on heteromeric ASIC1a/ASIC2a channels, since these channels are activated at pH 6.0 and are not inhibited by PcTx1 (Escoubas et al., 2003; Hesselager et al., 2004) . ASIC1a-containing channels have been shown to be involved in anxiety and fear in various animal models Coryell et al., 2007) . Thus, afobazole modulation of ASIC likely contributes to the anxiolytic properties of this drug.
Several studies have reported that afobazole is neuroprotective in vivo. In rats undergoing photothrombosis of vessels in the prefrontal cortex, application of afobazole 1 hr after ischemic stroke onset and for 8 days thereafter, reduced stroke volume by ~50% (Seredenin et al., 2008) .
Similarly, in two hemorrhagic stroke models, afobazole increased survival and improved motor outcomes when applied 3-6 hr after stroke onset and then twice daily for two weeks (Kraineva and Seredenin; Galaeva et al., 2005) . The in vitro observations presented here suggest that afobazole activation of σ receptors in vivo may contribute to the neuroprotective properties of this compound in both ischemic and hemorrhagic stroke. Our laboratory has previously shown that activation of σ receptors with DTG can significantly decrease stroke volume in the middle cerebral artery occlusion rat model of ischemic stroke (Ajmo et al., 2006) . Data shown here indicate that afobazole is a more potent neuroprotectant than DTG in an in vitro ischemia model. It remains to be determined if afobazole is more potent than DTG in vivo. Important from a therapeutic perspective, activation of σ receptors provides neuroprotection at delayed time points (Ajmo et al., 2006) . It is of significant interest to determine if afobazole can also decrease brain injury following stroke at delayed time points, and thus if it can extend the therapeutic window for effective stroke treatment.
In conclusion, afobazole effectively reduces [Ca 2+ ] i overload elicited by acidosis and in vitro ischemia in rat cortical neurons. Afobazole acts as an agonist at σ receptors to block these [Ca 2+ ] i
elevations. The inhibition of [Ca 2+ ] i overload during acidosis by afobazole was specifically linked to activation of σ-1 receptors by the compound. Afobazole was shown to be neuroprotective during ischemia, and afobazole-mediated inhibition of [Ca 2+ ] i overload likely accounts, at least in part, for the neuroprotection reported here. Given that afobazole has been shown to be safe when used clinically for anxiety, this drug represents a viable candidate for stroke therapy. Moreover, the effectiveness of σ receptor activation for neuroprotection at delayed time points following stroke suggests that afobazole may expand the therapeutic window for effective stroke therapy in humans.
This article has not been copyedited and formatted. The final version may differ from this version. neurons. Values for LDH in the absence of ischemia were normalized to control for neurons exposed to drug-free medium (Control) and in the presence of ischemia to values from medium containing 30 μM or 100 μM Afobazole (Afob 30 and Afob 100, respectively) or identical concentrations of DTG (DTG 30 and DTG 100, respectively). Ischemia groups were incubated in glucose-free medium containing 4 mM sodium azide and under hypoxic conditions for 2 hrs. LDH was measured in the medium after this period. The non-ischemia groups were incubated in control medium for the same duration under normoxic conditions and media collected at the same time.
For the DTG and afobazole treated groups, these drugs were applied in medium for 5 min prior to introduction of ischemia solution. Asterisks denote significant differences from Control group within Ischemia (p < 0.001) and pound symbols indicate significant difference between afobazole and DTG at 30 μM and 100 μM. Daggers denote difference between 30 μM and 100 μM concentrations of each drug. B, Percent inhibition of ischemia-induced cell death (relative to Control) produced by afobazole and DTG at 30 μM (Afob 30, DTG 30) and 100 μM (Afob 100, DTG 100) concentrations, respectively. Asterisk denotes significant difference between 30 μM and 100 μM afobazole and pound symbol indicates difference between 100 μM afobazole and 100 μM DTG (p < 0.05). For all groups, n > 9.
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